Back to articles

Two New Oncology Drugs Approved for U.S. Marketing


A pair of innovative new drugs for cancer have been approved by FDA. Bortezomib (Velcade—Millennium), the first in a new class of proteasome inhibitors, is indicated for third-line therapy for multiple myeloma. Tositumomab and iodine I 131 tositumomab (Bexxar—Corixa; GlaxoSmithKline) is a radiopharmaceutical agent used in the treatment of patients with CD20-positive, follicular, non-Hodgkin's lymphoma (NHL), with and without transformation, whose disease is refractory to rituximab (Rituxan—Genentech) and has relapsed following chemotherapy.


FDA bortezomib information page. http://www.fda.gov/cder/drug/infopage/velcade/velcadeQA.htm

Velcade prescribing information. http://www.millennium.com/products/velcade/full_prescrib_velcade.pdf

Millennium news release. http://www.millennium.com/media/news/2003/2003-05-13-0.asp

Bexxar Web site. http://www.bexxar.com